Avagliano Mark 4
4 · G1 Therapeutics, Inc. · Filed May 15, 2024
Insider Transaction Report
Form 4
Avagliano Mark
Chief Business Officer
Transactions
- Sale
Common Stock
2024-05-13$4.79/sh−8,151$39,034→ 209,683 total
Footnotes (3)
- [F1]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
- [F2]The price represents the weighted average price with a low of $4.62 and a high of $4.98. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Represents (i) 23,223 shares of common stock; (ii) 2,750 RSUs from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iii) 15,450 RSUs from award granted on January 3, 2023; (iv) 17,500 RSUs from award granted on May 10, 2023; (v) 44,760 RSUs from award granted on January 3, 2024; and (vi) 100,000 RSUs from award granted on March 20, 2024.